These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 11850290)

  • 1. Characterization of a new extended-spectrum beta-lactamase (TEM-87) isolated in Proteus mirabilis during an Italian survey.
    Perilli M; Segatore B; De Massis MR; Franceschini N; Bianchi C; Rossolini GM; Amicosante G
    Antimicrob Agents Chemother; 2002 Mar; 46(3):925-8. PubMed ID: 11850290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TEM-72, a new extended-spectrum beta-lactamase detected in Proteus mirabilis and Morganella morganii in Italy.
    Perilli M; Segatore B; de Massis MR; Riccio ML; Bianchi C; Zollo A; Rossolini GM; Amicosante G
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2537-9. PubMed ID: 10952610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TEM-89 beta-lactamase produced by a Proteus mirabilis clinical isolate: new complex mutant (CMT 3) with mutations in both TEM-59 (IRT-17) and TEM-3.
    Neuwirth C; Madec S; Siebor E; Pechinot A; Duez JM; Pruneaux M; Fouchereau-Peron M; Kazmierczak A; Labia R
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3591-4. PubMed ID: 11709345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New variant of TEM-10 beta-lactamase gene produced by a clinical isolate of proteus mirabilis.
    Palzkill T; Thomson KS; Sanders CC; Moland ES; Huang W; Milligan TW
    Antimicrob Agents Chemother; 1995 May; 39(5):1199-200. PubMed ID: 7625817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftazidime and aztreonam resistance in Providencia stuartii: characterization of a natural TEM-derived extended-spectrum beta-lactamase, TEM-60.
    Franceschini N; Perilli M; Segatore B; Setacci D; Amicosante G; Mazzariol A; Cornaglia G
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1459-62. PubMed ID: 9624494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nosocomial outbreak by Proteus mirabilis producing extended-spectrum beta-lactamase VEB-1 in a Korean university hospital.
    Kim JY; Park YJ; Kim SI; Kang MW; Lee SO; Lee KY
    J Antimicrob Chemother; 2004 Dec; 54(6):1144-7. PubMed ID: 15546971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Enzymatic resistance to beta lactam antibiotics within the genus Proteus and evaluation of Proteus mirabilis phenotypes and genotypes for resistance to third- and fourth-generation cephalosporins].
    Rodríguez C; Radice M; Perazzi B; Castro S; Juárez J; Santini P; Vay C; Famiglietti A; Gutkind G
    Enferm Infecc Microbiol Clin; 2005 Mar; 23(3):122-6. PubMed ID: 15757582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging extended-spectrum beta-lactamases in Proteus mirabilis.
    Pagani L; Migliavacca R; Pallecchi L; Matti C; Giacobone E; Amicosante G; Romero E; Rossolini GM
    J Clin Microbiol; 2002 Apr; 40(4):1549-52. PubMed ID: 11923394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolving beta-lactamase epidemiology in Enterobacteriaceae from Italian nationwide surveillance, October 2013: KPC-carbapenemase spreading among outpatients.
    Giani T; Antonelli A; Caltagirone M; Mauri C; Nicchi J; Arena F; Nucleo E; Bracco S; Pantosti A; ; Luzzaro F; Pagani L; Rossolini GM
    Euro Surveill; 2017 Aug; 22(31):. PubMed ID: 28797330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TEM-184, a Novel TEM-Derived Extended-Spectrum β-Lactamase with Enhanced Activity against Aztreonam.
    Piccirilli A; Perilli M; Amicosante G; Conte V; Tascini C; Rossolini GM; Giani T
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29941651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations.
    Luzzaro F; Perilli M; Amicosante G; Lombardi G; Belloni R; Zollo A; Bianchi C; Toniolo A
    Int J Antimicrob Agents; 2001 Feb; 17(2):131-5. PubMed ID: 11165117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TEM-187, a new extended-spectrum β-lactamase with weak activity in a Proteus mirabilis clinical strain.
    Corvec S; Beyrouthy R; Crémet L; Aubin GG; Robin F; Bonnet R; Reynaud A
    Antimicrob Agents Chemother; 2013 May; 57(5):2410-2. PubMed ID: 23478954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases.
    Endimiani A; Luzzaro F; Brigante G; Perilli M; Lombardi G; Amicosante G; Rossolini GM; Toniolo A
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2598-605. PubMed ID: 15980325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TEM-4, a new plasmid-mediated beta-lactamase that hydrolyzes broad-spectrum cephalosporins in a clinical isolate of Escherichia coli.
    Paul GC; Gerbaud G; Bure A; Philippon AM; Pangon B; Courvalin P
    Antimicrob Agents Chemother; 1989 Nov; 33(11):1958-63. PubMed ID: 2692515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Community spread of extended-spectrum β-lactamase-producing Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis: a long-term study in Japan.
    Chong Y; Shimoda S; Yakushiji H; Ito Y; Miyamoto T; Kamimura T; Shimono N; Akashi K
    J Med Microbiol; 2013 Jul; 62(Pt 7):1038-1043. PubMed ID: 23538565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. beta-Lactamases responsible for resistance to expanded-spectrum cephalosporins in Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis isolates recovered in South Africa.
    Pitout JD; Thomson KS; Hanson ND; Ehrhardt AF; Moland ES; Sanders CC
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1350-4. PubMed ID: 9624474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outbreak caused by Proteus mirabilis isolates producing weakly expressed TEM-derived extended-spectrum β-lactamase in spinal cord injury patients with recurrent bacteriuria.
    Cremet L; Bemer P; Rome J; Juvin ME; Navas D; Bourigault C; Guillouzouic A; Caroff N; Lepelletier D; Asseray N; Perrouin-Verbe B; Corvec S
    Scand J Infect Dis; 2011 Dec; 43(11-12):957-61. PubMed ID: 21888562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of an inhibitor-resistant enzyme IRT-2 derived from TEM-2 beta-lactamase produced by Proteus mirabilis strains.
    Bret L; Chanal C; Sirot D; Labia R; Sirot J
    J Antimicrob Chemother; 1996 Aug; 38(2):183-91. PubMed ID: 8877532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical analysis of TEM-134, a new TEM-type extended-spectrum beta-lactamase variant produced in a Citrobacter koseri clinical isolate from an Italian hospital.
    Perilli M; Celenza G; Fiore M; Segatore B; Pellegrini C; Luzzaro F; Rossolini GM; Amicosante G
    J Antimicrob Chemother; 2007 Oct; 60(4):877-80. PubMed ID: 17673478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of multidrug-resistant Proteus mirabilis in a long-term care facility in Croatia.
    Bedenić B; Firis N; Elveđi-Gašparović V; Krilanović M; Matanović K; Štimac I; Luxner J; Vraneš J; Meštrović T; Zarfel G; Grisold A
    Wien Klin Wochenschr; 2016 Jun; 128(11-12):404-13. PubMed ID: 27220339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.